DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Soo Hyeon | ko |
dc.contributor.author | Lee, Jeong Yu | ko |
dc.contributor.author | Kim, Jee Seon | ko |
dc.contributor.author | Park, Tae Gwan | ko |
dc.contributor.author | Mok, Hyejung | ko |
dc.date.accessioned | 2017-09-25T05:12:27Z | - |
dc.date.available | 2017-09-25T05:12:27Z | - |
dc.date.created | 2017-09-11 | - |
dc.date.created | 2017-09-11 | - |
dc.date.issued | 2017-08 | - |
dc.identifier.citation | BIOCONJUGATE CHEMISTRY, v.28, no.8, pp.2051 - 2061 | - |
dc.identifier.issn | 1043-1802 | - |
dc.identifier.uri | http://hdl.handle.net/10203/226003 | - |
dc.description.abstract | Combination therapy of nucleic acids and chemical drugs for cancer treatment is a promising strategy to enhance the therapeutic efficacy by simultaneously regulating multiple troublesome pathways. In this study, we report on polyethylene glycol-siRNA-polycaprolactone (PEG-siRNA-PCL) micelles that encapsulate hydrophobic drugs for efficient co-delivery of siRNA and drugs to cancer cells. Amphiphilic PEG-siRNA-PCL copolymers were synthesized by annealing antisense siRNA-PCL conjugates with sense siRNA-PEG conjugates. After paclitaxel encapsulation, PEG-siRNA-PCL micelles containing antiapoptotic Bcl-2-specific siRNA were stabilized with linear polyethylenimine via electrostatic interactions. Stabilized PEG-siRNA-PCL micelles showed superior anticancer effects, assessed by caspase-3 activity analysis, apoptotic cell staining, and a cytotoxicity test, to those of paclitaxel-free PEG-siRNA-PCL micelles and unmodified siRNAs. The strong anticancer activity of paclitaxel-incorporated siRNA micelles can be attributed to the synergistic effect of Bcl-2 siRNA and paclitaxel. This work provides an efficient co-delivery platform for combination anticancer therapy with siRNA and chemotherapy. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | TUMOR-GROWTH SUPPRESSION | - |
dc.subject | CANCER-TREATMENT | - |
dc.subject | LIPID NANOPARTICLES | - |
dc.subject | ANTICANCER DRUGS | - |
dc.subject | BREAST-CANCER | - |
dc.subject | GENE-THERAPY | - |
dc.subject | PACLITAXEL | - |
dc.subject | BCL-2 | - |
dc.subject | DOXORUBICIN | - |
dc.subject | MICELLES | - |
dc.title | Amphiphilic siRNA Conjugates for Co-Delivery of Nucleic Acids and Hydrophobic Drugs | - |
dc.type | Article | - |
dc.identifier.wosid | 000408075000006 | - |
dc.identifier.scopusid | 2-s2.0-85027451568 | - |
dc.type.rims | ART | - |
dc.citation.volume | 28 | - |
dc.citation.issue | 8 | - |
dc.citation.beginningpage | 2051 | - |
dc.citation.endingpage | 2061 | - |
dc.citation.publicationname | BIOCONJUGATE CHEMISTRY | - |
dc.identifier.doi | 10.1021/acs.bioconjchem.7b00222 | - |
dc.contributor.localauthor | Park, Tae Gwan | - |
dc.contributor.nonIdAuthor | Lee, Soo Hyeon | - |
dc.contributor.nonIdAuthor | Lee, Jeong Yu | - |
dc.contributor.nonIdAuthor | Kim, Jee Seon | - |
dc.contributor.nonIdAuthor | Mok, Hyejung | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | TUMOR-GROWTH SUPPRESSION | - |
dc.subject.keywordPlus | CANCER-TREATMENT | - |
dc.subject.keywordPlus | LIPID NANOPARTICLES | - |
dc.subject.keywordPlus | ANTICANCER DRUGS | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | GENE-THERAPY | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | BCL-2 | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | MICELLES | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.